SCHEMBL719968

SCHEMBL719968

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2oc3ccccc3c2C)C2CCCCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TSHR P16473 2/20 0.37
HSD17B10 Q99714 1/20 0.37
HCRTR1 O43613 1/20 0.36
TP53 P04637 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
TEAD4 Q15561 1/20 0.35
HTT P42858 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 1/20 0.35
PKM P14618 1/20 0.35
VKORC1 Q9BQB6 2/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716552 0.91 NPC1 (0.40) NPC1RAB9AHCRTR1TP53L3MBTL1
SCHEMBL718770 0.91 KMT2A (0.35) NPC1RAB9ATSHRHSD17B10TP53
SCHEMBL718427 0.91 KMT2A (0.35) NPC1RAB9ATSHRHSD17B10TP53
SCHEMBL721953 0.90 DGAT1 (0.36) TSHRL3MBTL1TEAD4MEN1KMT2A
SCHEMBL719324 0.89 MAPT (0.36) NPC1RAB9ATSHRHSD17B10TP53
SCHEMBL716825 0.89 NPC1 (0.41) NPC1RAB9ATSHRTP53TEAD4
SCHEMBL718485 0.89 PIK3CB (0.35) NPC1RAB9AHSD17B10L3MBTL1TEAD4
SCHEMBL720981 0.89 KMT2A (0.34) NPC1RAB9ATSHRHSD17B10TP53
SCHEMBL716683 0.88 NPC1 (0.43) NPC1RAB9ATSHRTP53L3MBTL1
SCHEMBL720867 0.88 KMT2A (0.34) NPC1RAB9ATSHRHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885TSHR 1555/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885TSHR 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.